Navigation Links
Increased Investments in New Drug Development Drives Demand for Cell-Based Assays, According to an Upcoming Report by Global Industry Analysts, Inc.

San Jose, California (PRWEB) July 17, 2014

Follow us on LinkedIn – GIA is pleased to announce the launch of a major research program analysing the trends impacting the market for “Cell-Based Assays”. Invited to participate in this comprehensive grassroots level global research initiative are senior industry executives, domain experts, technologists and market strategists. The new report to be issued shortly will offer accurate assessment of global market developments including major technologies, trends and challenges, together with descriptive, exploratory, and quantitative analysis of major product and geographic market segments. For details about how you can participate in this primary research program to include your inputs prior to the publication, please click here.

The drug discovery sector is the major end-user of cell-based assays. Characterized by versatility, cell-based assays represent a powerful research tool that provides valuable information for successful R&D. Cell-based assays also facilitate in studying biological characteristics of target drug compounds and their impact on cells/cellular systems in terms of activation of cell receptors, alteration in gene activity and expression of proteins. These assays are therefore emerging as a preferred tool for screening potential drug molecules. Cell-based assays also play an important role in toxicology testing in early stages of drug discovery, thereby reducing overall costs and the risk of clinical trial failures. Additionally, the market is being driven by the availability of high throughput screening (HTS) systems and advanced technological innovations such as development of label-free cell-based assays. Growing focus on expansion of drug portfolios and the ensuing increased investments in new drug development by pharma majors will generate lucrative opportunities for growth in the coming years.

The upcoming report will offer coverage on major companies including BD Biosciences, Beckman Coulter Inc., EMD Millipore, GE Healthcare Life Sciences, Life Technologies Corp, and Qiagen NV, among others.

In addition, the study will also provide:

  •     Valuable market based intelligence on new emerging trends, growth drivers, issues and challenges.
  •     Current coverage on company information and latest news and events including strategic corporate developments, and product innovations
  •     Fresh research perspectives, statistical findings, analyst analysis, and commentaries
  •     Accurate market estimates, projections, and forecasts across major market segments (Assay Kits (Functional Assays, Cell Death-Associated Assays, Cell Growth-Associated Assays) and Laboratory Automation) and geographic regions (the United States, Japan, Europe, and Rest of World).

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:


Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Hospital-Diagnosed Maternal Infections Linked to Increased Autism Risk
2. New Genedata Expressionist for Mass Spectrometry Gains Increased Adoption in Metabolomics R&D
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. SoundConnect Responds to Increased, Cost-Effective Unified Communications Demands Through Agent Partnership Program
5. Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year
6. High-flying pilots at increased risk of brain lesions
7., Major Liquid Handling Distributor, Has Increased Their Bottletop Dispenser Stock
8. Kitware to Develop an In Situ Cosmology Analysis Framework for Increased Understanding of the Universe
9. SPIE Encouraged By Increased Science Funding in Obama Budget, Urges Applied Research Emphasis
10. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
11. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):